ASGE Masterclass: Barrett’s Esophagus, GERD and Esophageal Adenocarcinoma (On Demand) | February 2022-Changing the Natural History of Barrett's Aspirin, High Dose PPI, Ablation for all?

Changing the Natural History of Barrett's Aspirin, High Dose PPI, Ablation for all?

Video Transcription

Video Summary

In this video, the speaker discusses the natural history of battered esophagus, risk factors for progression, and the role of aspirin and PPI therapy for chemoprevention. The speaker also reviews the latest ASGE guidelines and mentions various statistics related to battered esophagus and esophageal cancer. They talk about the risk of cancer in battered patients and how it is higher for patients who start with early onset GERD symptoms before age 30. The video also mentions the risk of progression to low-grade dysplasia and high-grade dysplasia. The role of PPIs as chemopreventive agents is discussed, along with studies and meta-analyses on their effectiveness. The ASPECT trial, which looked at the benefit of giving high-dose PPIs versus low-dose PPIs, is mentioned. The video also covers other chemopreventive agents such as aspirin, NSAIDs, statins, and metformin. The role of endoscopic eradication therapy in non-dysplastic batters, low-grade dysplasia, and high-grade dysplasia is discussed. Risk stratification using p53 mutation, tissue cycle assay, and the progressor’s in Barrett's risk prediction model is also mentioned. The video ends with a summary of recommendations for management of non-dysplastic patients, low-grade dysplasia patients, and high-grade dysplasia patients according to the ASGE guidelines. No credits were granted in the video.

Keywords

battered esophagus

PPI therapy

ASGE guidelines

esophageal cancer

chemopreventive agents

endoscopic eradication therapy